Granza Bio is an early-stage biotechnology company reprogramming immunity for target-specific medicines. Founded in 2024 by Dr. Ashwin Nandakumar, Dr. Ashwin Jainarayanan, and Prof. Michael Dustin, the company builds on the discovery of "attack particles" — killing entities released by cytotoxic immune cells, characterized in Prof. - View it on GitHub